Design and rationale of Lp(a)HORIZON trial: Assessing the effect of Lipoprotein(a) lowering with Pelacarsen on major cardiovascular events in patients with CVD and elevated Lp(a)
作者:Leslie Cho [1];Stephen J. Nicholls [2];Børge G. Nordestgaard [3];Ulf Landmesser [4];Sotirios Tsimikas [5];Michael J. Blaha [6];Eran Leitersdorf [7];A. Michael Lincoff [8];Anastasia Lesogor [9];Brian Manning [10];Plamen Kozlovski [11];Hui Cao [12];Jing Wang [13];Steven E. Nissen [14];
DOI:10.1016/j.ahj.2025.03.019